parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 15037

RGS20 in dopamine neurons, braak-0.48 (p 0.186) → +0.19 (p 0.618)receipt 15045
RGS20 in astrocytes, braak+0.25 (p 0.508) → -0.37 (p 0.329)receipt 15044

receipt 15045: RGS20 in dopamine neurons, braak

power: full sample -0.18 (p 0.476, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.471, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.434, n 18). could be the mix.
skeptic: leave-one-out range -0.33 to -0.07, sign flips 0; without severely affected donors -0.18 (p 0.476, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RGS20 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15044: RGS20 in astrocytes, braak

power: full sample -0.01 (p 0.956, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.00 (p 0.997, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.04 (p 0.861, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.09, sign flips 7; without severely affected donors -0.01 (p 0.956, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RGS20 in astrocytes.

case closed: nothing better to follow up.

loading the receipts